Somewhat Positive Press Coverage Somewhat Unlikely to Affect Pernix Therapeutics (PTX) Share Price

News coverage about Pernix Therapeutics (NASDAQ:PTX) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pernix Therapeutics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.5041953002352 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Pernix Therapeutics (NASDAQ PTX) traded down $0.11 during trading hours on Tuesday, hitting $2.60. 101,400 shares of the company were exchanged, compared to its average volume of 397,166. The company has a current ratio of 0.99, a quick ratio of 0.91 and a debt-to-equity ratio of -0.80. Pernix Therapeutics has a 52 week low of $1.83 and a 52 week high of $7.15.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at

Pernix Therapeutics Company Profile

Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.

Insider Buying and Selling by Quarter for Pernix Therapeutics (NASDAQ:PTX)

Receive News & Ratings for Pernix Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics Holdings Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply